News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
London, January 8, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 1:30pm PT / 9:30pm GMT. The webcast is available through this link.
Mereo BioPharma Provides Corporate Update
London, January 12, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its programs, setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, which is being studied for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), and revised its cash runway guidance.
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
London, December 29, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases, today announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI).
Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
LONDON and REDWOOD CITY, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing
Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress
Mereo BioPharma Group today announced additional endpoint data from the Company’s Phase 2b dose-ranging "ASTEROID" clinical study of setrusumab (BPS-804), an anti-sclerostin antibody, in adults with Type I, III or IV osteogenesis imperfecta (“OI”)
Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
Dose-Dependent and Statistically Significant Improvement in Areal Bone Mineral Density (BMD) Over Baseline at the Lumbar Spine, as Measured by DXA, Reaching 8.8% at 12 Months in Highest Dose Cohort (p
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs
LONDON and REDWOOD CITY, Calif. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Christine Fox , CPA, as Chief
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020 Plans to host virtual R&D day to review etigilimab development program and rare disease product pipeline in November 2020 LONDON and REDWOOD CITY, Calif. , Oct.
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
LONDON and REDWOOD CITY, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S.
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking Oral Presentation at ASBMR 2019 Conference Call Today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and REDWOOD CITY, Calif.
Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 17, 2019
LONDON and REDWOOD CITY, Calif. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces that it will release interim financial results for
Mereo BioPharma Announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta Selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
Mereo BioPharma Group a clinical stage biopharmaceutical company focused on rare diseases, today announces that the 6-month interim data from the open label arm of the Company’s Phase 2b dose-ranging “ASTEROID” clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) have been selected for a late-breaking oral presentation at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
LONDON and REDWOOD CITY, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment of Richard Francis as Head of Pharmaceutical Development , effective August 1.
Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Update on Etigilimab (TIGIT) Partnership
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif. , June 13, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc
